A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

James G. Krueger; Mayte Suárez-Fariñas; Inna Cueto; Artemis Khacherian; Robert Matheson; Lawrence C. Parish; Craig Leonardi; Denise Shortino; Akanksha Gupta; Jonathan Haddad; George P. Vlasuk; Eric W. Jacobson

doi:10.1371/journal.pone.0142081

Loading metrics

Open Access

Peer-reviewed

Research Article

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

James G. Krueger,

Affiliation Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, United States of America
⨯
Mayte Suárez-Fariñas,

Affiliations Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, United States of America, Center for Clinical and Translational Science, The Rockefeller University, New York, New York, United States of America
⨯
Inna Cueto,

Affiliation Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, United States of America
⨯
Artemis Khacherian,

Affiliation Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, United States of America
⨯
Robert Matheson,

Affiliation Oregon Medical Research Center, PC, Portland, Oregon, United States of America
⨯
Lawrence C. Parish,

Affiliation Paddington Testing Co, Inc., Philadelphia, Pennsylvania, United States of America
⨯
Craig Leonardi,

Affiliation Central Dermatology, St. Louis, Missouri, United States of America
⨯
Denise Shortino,

Affiliation Clinical Statistics, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America
⨯
Akanksha Gupta ,

* E-mail: akanksha.x.gupta@gsk.com

Affiliation Sirtris, a GlaxoSmithKline Company, Cambridge, Massachusetts, United States of America
⨯
Jonathan Haddad,

Affiliation Clinical Statistics, GlaxoSmithKline, Research Triangle Park, North Carolina, United States of America
⨯
George P. Vlasuk,

Affiliation Sirtris, a GlaxoSmithKline Company, Cambridge, Massachusetts, United States of America
⨯
Eric W. Jacobson

Affiliation Sirtris, a GlaxoSmithKline Company, Cambridge, Massachusetts, United States of America
⨯

A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis

James G. Krueger,
Mayte Suárez-Fariñas,
Inna Cueto,
Artemis Khacherian,
Robert Matheson,
Lawrence C. Parish,
Craig Leonardi,
Denise Shortino,
Akanksha Gupta,
Jonathan Haddad

Published: November 10, 2015
https://doi.org/10.1371/journal.pone.0142081

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Psoriasis
Is the Subject Area "Psoriasis" applicable to this article?

Thanks for your feedback.
Keratinocytes
Is the Subject Area "Keratinocytes" applicable to this article?

Thanks for your feedback.
Histology
Is the Subject Area "Histology" applicable to this article?

Thanks for your feedback.
Biopsy
Is the Subject Area "Biopsy" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Gene expression
Is the Subject Area "Gene expression" applicable to this article?

Thanks for your feedback.
Inflammation
Is the Subject Area "Inflammation" applicable to this article?

Thanks for your feedback.
Adverse events
Is the Subject Area "Adverse events" applicable to this article?

Thanks for your feedback.